Abstract
The Selenium and Vitamin E Cancer Prevention Trial (SELECT) randomized 35,533 healthy men, ≥55 years (≥50 years if African American), with normal digital rectal exams and prostate-specific antigens <4 ng/mL, to (i) 200 μg/day l-selenomethionine, (ii) 400 IU/day all-rac-alpha-tocopheryl acetate (vitamin E), (iii) both supplements, or (iv) placebo for a median of 5.5 years (range 4.2–7.3 years). The hypotheses underlying SELECT, that selenium and vitamin E individually and together decrease prostate cancer incidence, derived from epidemiologic and laboratory evidence and significant secondary endpoints in the Nutritional Prevention of Cancer (NPC) (selenium) and Alpha-Tocopherol Beta-Carotene (vitamin E) trials. Results from SELECT showed that prostate cancer incidence did not differ among the four arms: hazard ratios (HRs) (99% CIs) for prostate cancer: 1.13 (99% CI, 0.95–1.35; p = 0.06; n = 473) for vitamin E, 1.04 (99% CI, 0.87–1.24; p = 0.62; n = 432) for selenium, and 1.05 (99% CI, 0.88–1.25; p = 0.52; n = 437) for selenium + vitamin E vs. 1.00 (n = 416) for placebo. Statistically nonsignificant increased risks of prostate cancer with vitamin E alone (RR 1.13; p = 0.06) and newly diagnosed type 2 diabetes mellitus with selenium alone (RR 1.07; p = 0.16) were observed. SELECT data show that neither selenium nor vitamin E, alone or together, in the doses and formulations used, prevented prostate cancer in this heterogeneous population of healthy men. Although there are many potential explanations for the null findings in SELECT, the most likely reasons appear to be a mismatch between the target population and the intervention agents selected, or that effects were limited to as-yet-undetermined subgroups of susceptible men.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Clark LC, Combs GF Jr, Turnbull BW et al (1996) JAMA 276:1957
The Alpha-Tucopheral, Beta-Carotene Cancer Prevention Study Group (1994) N Engl J Med 330:1029
Heinonen OP, Albanes D, Virtamo J et al (1998) J Natl Cancer Inst 90:440
Klein EA, Thompson IM, Lippman SM et al (2000) Prostate Cancer Prostatic Dis 3:145
Klein EA, Thompson IM, Lippman SM et al (2001) J Urol 166:1311
Klein EA, Thompson IM, Lippman SM et al (2003) Urol Oncol 21:59
Lippman SM, Goodman PJ, Klein EA et al (2005) J Natl Cancer Inst 97:94
Hoque A, Albanes D, Lippman SM et al (2001) Cancer Causes Control 12:627
Hartman TJ, Albanes D, Pietinen P et al (1998) Cancer Epidemiol Biomarkers Prev 7:335
NIH (2009) Vitamin E. In: National Institutes of Health Office of Dietary Supplements. http://ods.od.nih.gov/factsheets/vitamine.asp. Accessed 30 December 2010
Sano M, Ernesto C, Thomas RG et al (1997) N Engl J Med 336:1216
Age-Related Eye Disease Study Research Group (2001) Arch Ophthalmol 119:1417
Lippman SM, Klein EA, Goodman PJ et al (2009) JAMA 301:39
Cook ED, Moody-Thomas S, Anderson KB et al (2005) Clin Trials 2:436
Traber MG (2008) Nutr Rev 66:624
Stranges S, Marshall JR, Natarajan R et al (2007) Ann Intern Med 147:217
Kristal AR (2008) Cancer Epidemiol Biomarkers Prev 17:3289
Powles TJ, Ashley S, Tidy A et al (2007) JNCI 99:283
Waters DJ, Shen S, Glickman LT et al (2005) Carcinogenesis 26:1256
Mertz W (1981) Science 213:1332
Patterson BH, Levander OA (1997) Cancer Epidemiol Biomarkers Prev 6:63
Bekaert B, Rayman MP (2009) Am J Clin Nutr 89:1276; author reply 1277
Clark LC, Dalkin B, Krongrad A et al (1998) Br J Urol 81:730
Duffield-Lillico AJ, Dalkin BL, Reid ME et al (2003) BJU Int 91:608
Kryukov GV, Castellano S, Novoselov SV et al (2003) Science 300:1439
Li H, Kantoff PW, Giovannucci E et al (2005) Cancer Res 65:2498
Penney KL, Schumacher FR, Li H et al (2010) Cancer Prev Res 3:604
Ip C (1998) J Nutr 128:1845
Ip C, Thompson HJ, Zhu Z et al (2000) Cancer Res 60:2882
Raich PC, Lu J, Thompson HJ et al (2001) Cancer Invest 19:540
Hatfield DL, Gladyshev VN (2009) Mol Interv 9:18
Menter DG, Sabichi AL, Lippman SM (2000) Cancer Epidemiol Biomarkers Prev 9:1171
Lu J, Jiang C, Kaeck M et al (1995) Biochem Pharmacol 50:213
Li JD, Mehrotra DV (2008) Biom J 50:704
Freemantle N (2001) Br Med J 322:989
Allen NE, Key TJ (2009) Nat Rev Urol 6:187
Acknowledgements
This work was supported by the National Cancer Institute’s Division of Cancer Prevention; and the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Division of Cancer Epidemiology and Genetics. We also gratefully acknowledge the input and support of this effort by Ellen S Richmond, Lori M Minasian, Anne M Ryan, and Leslie G Ford of the Division of Cancer Prevention.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Dunn, B.K., Taylor, P.R. (2011). Prostate Cancer Prevention and the Selenium and Vitamin E Cancer Prevention Trial (SELECT): A Selenium Perspective. In: Hatfield, D., Berry, M., Gladyshev, V. (eds) Selenium. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-1025-6_23
Download citation
DOI: https://doi.org/10.1007/978-1-4614-1025-6_23
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-1024-9
Online ISBN: 978-1-4614-1025-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)